Abstract
The bisindole indirubin has been described, more than 30 years ago, as being clinically active in the treatment of human chronic myelocytic leukaemia. However, the underlying mechanism of action has remained unclear. We have reported previously that indirubin and its analogues are potent and selective inhibitors of cyclin-dependent kinases (CDK). In this study, we investigated the influence of indirubin and derivatives on CDK1/cyclin B kinase in human tumour cells at concentrations known to induce growth inhibition. Cells of the mammary carcinoma cell line MCF-7, synchronized by serum deprivation, after serum repletion stay arrested in the G1/G0phase of the cell cycle in the presence of 2 μM indirubin-3′-monoxime. At higher drug concentrations (≥ 5 μM) an increase of the cell population in the G2/M phase is additionally observed. Cells synchronized in G2/M phase by nocodazole remain arrested in the G2/M phase after release, in the presence of indirubin-3′-monoxime (≥5 μM). After 24 h treatment with 10 μM indirubin-3′-monoxime a sub-G2 peak appears, indicative for the onset of apoptotic cell death. Treatment of MCF-7 cells with growth inhibitory concentrations of indirubin-3′-monoxime induces dose-dependent inhibition of the CDK1 activity in the cell. After 24 h treatment, a strong decrease of the CDK1 protein level along with a reduction of cyclin B in complex with CDK1 is observed. Taken together, the results of this study strongly suggest that inhibition of CDK activity in human tumour cells is a major mechanism by which indirubin derivatives exert their potent antitumour efficacy. © 2001 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Abraham RT, Acquarone M, Andersen A, Asensi A, Bellé R, Berger F, Bergounioux C, Brunn G, Buquet-Fagot C, Fagot D, Glab N, Goudeau H, Goudeau M, Guerrier P, Houghton P, Hendriks H, Kloareg B, Lippai M, Marie D, Maro B, Meijer L, Mester J, Mulner-Lorillon O, Poulet SA, Schierenberg E, Schutte B, Vaulot D and Verlhac MH (1995) Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. Biol Cell 83: 105–120 Chinese Pharmacopoeia, Edition 1995, Vol. 1
Chen DH and Xie JX (1984) Chemical constituents of traditional Chinese medicine Qing Dai. Chinese Trad Herbal Drugs 15: 6–8
Cooperative Group of Clinical Therapy of Indirubin (1980) Clinical studies of 314 cases of CML treated with indirubin. Chinese J Intern Med 1: 132–135
Fiebig HH, Berger DP, Dengler WA, Wallbrecher E and Winterhalter BR (1992) Combined in vitro/in vivo test procedure with human tumor xenografts for new drug development. In: HH Fiebig, DP Berger (eds), Contrib. Oncol. Vol. 42: Immunodeficient Mice in Oncology, Basel: Karger, pp. 321–351
Hoessel R, Leclerc S, Endicott JA, Noble MEM, Lawrie A, Tunnah P, Leost M, Damiens E, Marie D, Marko D, Niederberger E, Tang W, Eisenbrand G and Meijer L (1999) Indirubin, the active constituent of a Chinese antileukemia medicine, inhibits cyclin-dependent kinases. Nature Cell Biology 1: 60–67
Institute of Haematology Chinese Academy of Medical Sciences (1979) Clinical studies of Dang Gui Lu Hui Wan in the treatment of CML. Chinese Journal of Internal Medicine 15: 86–88
Marko D, Romanakis K, Zankl H, Fuerstenberger G, Steinbauer B and Eisenbrand G (1998) Induction of apoptosis by an inhibitor of cAMP-specific PDE in malignant murine carcinoma cells overexpressing PDE activity in comparison to their nonmalignant counterpart. Cell Biochem Biophys 28: 75–101
Skehan P, Storeng R, Scudiero D, Monks A, McMahon J, Vistica D, Warren JT, Bokesch H, Kenney S and Boyd MR (1990) New colorimetric assay for anticancer-drug screening. J Natl Cancer Inst 82: 1107–1112
Takizawa GG, Weis K and Morgan DO (1999) Ran-independent nuclear import of cyclin B1-cdc2 by importin β. Proc Natl Acad Sci USA 96: 7938–7943
Wu LM, Yang YP and Zhu ZH (1979) Studies on the active principles of indigofera tinctoria in the treatment of CML. Comm Chinese Herbal Med 9: 6–8
Wu GY, Fang FD, Liu JZ, Chang A and Ho YH (1980) Studies on the mechanism of action of indirubin in the treatment of chronic granulocytic leukemia. I. Effects on nucleic acid and protein synthesis in human leukemic cells. Chinese Medical J 60: 451–454
Zheng QT, Lu DJ and Yang SL (1979) Pharmacological studies of indirubin. I. Antitumor effect. Comm Chinese Herbal Med 10: 35–39
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Marko, D., Schätzle, S., Friedel, A. et al. Inhibition of cyclin-dependent kinase 1 (CDK1) by indirubin derivatives in human tumour cells. Br J Cancer 84, 283–289 (2001). https://doi.org/10.1054/bjoc.2000.1546
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1054/bjoc.2000.1546
Keywords
This article is cited by
-
Indigofera suffruticosa aerial parts extract induce G2/M arrest and ATR/CHK1 pathway in Jurkat cells
BMC Complementary Medicine and Therapies (2024)
-
Transcriptome Analysis of Nitrogen Metabolism, Transcription Factors, and Indigoid Biosynthesis in Isatis indigotica Fort. Response to Nitrogen Availability
Journal of Plant Growth Regulation (2021)
-
Transcriptome-wide Profiling of Cerebral Cavernous Malformations Patients Reveal Important Long noncoding RNA molecular signatures
Scientific Reports (2019)
-
Induction of atypical cell death in thyroid carcinoma cells by the indirubin derivative 7-bromoindirubin-3′-oxime (7BIO)
Cancer Cell International (2015)
-
Molecular dynamics study of the inhibitory effects of ChEMBL474807 on the enzymes GSK-3β and CDK-2
Journal of Molecular Modeling (2015)